Georgina Loya
Family Medicine · Houston, TXNPI 1912915158
Payments from drug & device makers
Across 164 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$880
- Lilly USA, LLC$642
- Novo Nordisk$415
- Amgen$340
- Boehringer Ingelheim$129
- Merck$98
- plus $485 from 11 others
What the payments were for
- Food & beverage$2,976100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $880 |
| Lilly USA, LLC | 34 | $642 |
| Novo Nordisk | 29 | $415 |
| Amgen | 19 | $340 |
| Boehringer Ingelheim | 7 | $129 |
| Merck | 7 | $98 |
| Pfizer | 4 | $91 |
| Exact Sciences | 4 | $77 |
| Amarin Pharma, Inc. | 4 | $65 |
| Abbott | 3 | $61 |
| Johnson & Johnson | 3 | $58 |
| Astellas Pharma US Inc | 2 | $50 |
| GSK | 1 | $23 |
| AbbVie | 1 | $18 |
| Vivus LLC | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
How this compares
$2,989 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $75,106 |
| FarxigaDapagliflozin Propanediol | 35 | $46,490 |
| JardianceEmpagliflozin | 24 | $35,305 |
| JanuviaSitagliptin Phosphate | 15 | $19,087 |
| Atorvastatin Calcium | 263 | $3,795 |
| Rosuvastatin Calcium | 157 | $3,792 |
| Losartan Potassium | 154 | $2,372 |
| Metoprolol Succinate | 113 | $2,329 |
| Solifenacin Succinate | 14 | $1,897 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 69 | $1,892 |
| Alendronate Sodium | 170 | $1,714 |
| Fluticasone Propionate | 78 | $1,551 |
| Metformin Hcl | 193 | $1,401 |
| Pioglitazone Hcl | 37 | $1,386 |
| Nifedipine ErNifedipine | 17 | $1,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $415 | $75,10642 claims |
| AstraZenecaFarxiga | $880 | $46,49035 claims |
| Boehringer IngelheimJardiance | $129 | $35,30524 claims |
| MerckJanuvia | $98 | $19,08715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Houston
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
- Bonnie ColvilleHouston$19.6M
- Oscar de ValleHouston$12.8M
- van TranHouston$11M
- Joe PouzarHouston$10.7M
- Aalia Al-BarwaniHouston$6.8M
- Terence ChangHouston$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.